Structure Encountered
ReST Therapeutics
Develops small molecule NMDA antagonist to prevent PTSD after trauma
ReST cleared FDA IND for RST-101, an NMDA antagonist aimed at preventing PTSD after trauma.
SIGNAL·IND accepted (Phase 1 cleared)·FDA IND accepted·SCORE 72·02 JUN 2026 · 11:54 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / REST THERAPEUTICS
/ Paris, France and New Haven, Connecticut
CAPT. / 02.06.26 11:54:29Z
SIGNAL / 72 / 100
Image relayed by The Biotech Voyager during pass over structure ReST Therapeutics. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
ReST Therapeutics
Coordinates
Paris, France and New Haven, Connecticut
Stage
Phase1
Type
Therapeutics
Modalities
small molecule
Therapeutic area
Psychiatry · Neurology · Rare Disease
002Signature Detected
EVENT DETECTED
Event type
IND accepted (Phase 1 cleared)
Magnitude
FDA IND accepted
Lead
ReST Therapeutics
Participating
First-in-human Phase 1 in healthy volunteers; safety, PK, food effect
003Architecture
PLATFORM PROFILE
Target class
NMDA receptor subtypes 2C and 2D. RST-101 is a selective small-molecule antagonist meant to modulate trauma memory consolidation in the early window after a traumatic event.
Differentiator
Approved PTSD options and the psychedelic wave both treat established, chronic PTSD. RST-101 flips the timing: give it in the days after trauma to keep the disorder from consolidating in the first place, using an unusual 2C/2D-selective mechanism.
Lead asset
RST-101 (NMDAR 2C/2D antagonist), Phase 1 cleared
Pipeline depth
1 lead (RST-101, early PTSD); preclinical interest in Alzheimer's
004Voyager Assessment
MACHINE-GENERATED
Most PTSD work, including the MDMA wave, treats the disorder years after it sets in. ReST is asking a different question: what if you could stop it from forming? RST-101 is a small-molecule NMDA antagonist tuned to the 2C and 2D subtypes, given in the early window after trauma to interfere with how the brain consolidates the memory. It's a clean idea with a long scientific lineage, the propranolol reconsolidation studies and so on, that nobody has turned into an approved drug. The FDA has cleared the IND, so this is healthy-volunteer Phase 1, years from proving the prevention thesis.
005Adjacent Structures
FRONTIER MAP
Lykos Therapeutics· MDMA-assisted PTSDTranscend Therapeutics· methylone for PTSDTonix Pharmaceuticals· TNX-102 PTSDOtsuka· brexpiprazole combo, PTSDBionomics· BNC210, anxiety and PTSDAddex Therapeutics· mGlu7, fear memory
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.